WELLS FARGO & COMPANY/MN - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 59 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.

Quarter-by-quarter ownership
WELLS FARGO & COMPANY/MN ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$8,079
-89.5%
40,377
+8.1%
0.00%
Q2 2023$76,949
-6.0%
37,354
+50.6%
0.00%
Q1 2023$81,866
+151.2%
24,808
+24.8%
0.00%
Q4 2022$32,588
-63.8%
19,871
-2.5%
0.00%
Q3 2022$90,000
+80.0%
20,383
+13.9%
0.00%
Q2 2022$50,000
-9.1%
17,897
+10.3%
0.00%
Q1 2022$55,000
-25.7%
16,225
-12.6%
0.00%
Q4 2021$74,000
+68.2%
18,558
+40.8%
0.00%
Q3 2021$44,000
-10.2%
13,182
+2.9%
0.00%
Q2 2021$49,000
-57.8%
12,806
-58.1%
0.00%
Q1 2021$116,000
-75.1%
30,568
-70.2%
0.00%
Q4 2020$465,000
-59.3%
102,670
+52.1%
0.00%
Q3 2020$1,142,000
+71.7%
67,491
+13.8%
0.00%
Q2 2020$665,000
+811.0%
59,332
+280.3%
0.00%
Q1 2020$73,000
+247.6%
15,603
+212.1%
0.00%
Q4 2019$21,000
+5.0%
5,0000.0%0.00%
Q3 2019$20,0000.0%5,000
-2.6%
0.00%
Q2 2019$20,000
-9.1%
5,132
+2.6%
0.00%
Q1 2019$22,000
+22.2%
5,0000.0%0.00%
Q4 2018$18,000
-67.9%
5,000
-65.6%
0.00%
Q3 2018$56,0000.0%14,545
+1.4%
0.00%
Q2 2018$56,000
+24.4%
14,3450.0%0.00%
Q1 2018$45,000
+2.3%
14,345
+26.4%
0.00%
Q4 2017$44,000
+76.0%
11,345
+89.1%
0.00%
Q3 2017$25,000
+19.0%
6,000
+20.0%
0.00%
Q2 2017$21,0000.0%5,0000.0%0.00%
Q1 2017$21,000
+110.0%
5,000
+25.0%
0.00%
Q4 2016$10,0000.0%4,0000.0%0.00%
Q3 2016$10,0004,0000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q3 2023
NameSharesValueWeighting ↓
Weaver Consulting Group 130,000$437,0000.21%
Ikarian Capital, LLC 304,161$1,022,0000.13%
ABNER HERRMAN & BROCK LLC 265,000$890,0000.12%
S.C. Financial Services, Inc. 15,285$51,0000.06%
JMAC ENTERPRISES LLC 45,430$153,0000.04%
CFO4Life Group, LLC 12,000$40,0000.01%
OSAIC HOLDINGS, INC. 10,839$1,329,0000.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$10,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 29,186$98,0000.00%
RAYMOND JAMES & ASSOCIATES 190,403$640,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders